PRC200-SS

PRC200-SS
Identifiers
  • (1S,2S)-3-(Methylamino)-2-naphthalen-2-yl-1-phenylpropan-1-ol
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
ECHA InfoCard100.207.294 Edit this at Wikidata
Chemical and physical data
FormulaC20H21NO
Molar mass291.394 g·mol−1
3D model (JSmol)
  • O[C@H](c1ccccc1)[C@H](CNC)c2cc3ccccc3cc2
  • InChI=1S/C20H21NO/c1-21-14-19(20(22)16-8-3-2-4-9-16)18-12-11-15-7-5-6-10-17(15)13-18/h2-13,19-22H,14H2,1H3/t19-,20-/m1/s1 ☒N
  • Key:RSZGIFQDUIROGN-WOJBJXKFSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.[1][2]

Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development.

References

[edit]
  1. ^ Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, et al. (November 2008). "Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 573–83. doi:10.1124/jpet.108.143610. PMID 18689611. S2CID 12635418.
  2. ^ "Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures.
  3. ^ Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, et al. (April 2011). "Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor". Toxicological Sciences. 120 (2): 269–83. doi:10.1093/toxsci/kfr013. PMID 21258088.
Retrieved from "https://en.wikipedia.org/w/index.php?title=PRC200-SS&oldid=1120772415"